超声微泡介导新型小分子Nutlin3治疗眼内黑色素瘤的研究

Intraocular melanoma is the most severe and intractable disease in ophthalmology. Researchers have been dedicated to study efficient, safe, and targeted anti-tumor strategies for years. Traditional radiotherapy, chemotherapy and surgical removal are of varying degrees of visual impairment, systemic side effects, or even risk of disability. With recent advances of microbubble-delivered drug or gene therapy, microbubble technique has been applied in the diagnosis and treatment of cancers. As non-invasive, non-toxic, and non-radioactive gas bubbles measured less than 10 micrometers with nanometers of shell membrane, microbubbles can release loaded-drug in targeted regions, which could not only decrease systemic side effects, but also increase local drug delivery. Nutlin3 is a recently developed small molecule of cis-imidazoline. This potent anti-tumor novel molecule can affect the interaction of MDM2 and p53, inhibiting p53-dependent cell proliferation. Our proposed research aims to study the utility and efficacy of microbubble-delivered novel small-molecule Nutlin3 for the treatment of intraocular melanoma, in order to provide new approaches of anti-eye tumor therapy.

眼内黑色素瘤是眼病中性质最严重、危害最大的一类。一直以来研究学者都在不断探索高效、安全、靶向的抗肿瘤方案。传统的放疗、化疗以及手术摘除均存在不同程度视力损害及全身毒副作用，甚至有致畸致残的危险。随着超声微泡技术的不断发展和可携带药物、基因的微泡造影剂的研制，超声微泡在肿瘤的诊断与治疗方面取得了进展。作为一种新型的药物载体，超声微泡具有无创、无毒、无放射污染等优点，能将携带的药物定向释放在靶组织，既减少药物在外周的破坏, 降低全身用药的副作用，又能显著提高局部组织的药物浓度。Nutlin3是近年来研发的咪唑其类小分子，能抑制MDM2与p53的相互作用，导致p53依赖的生长抑制，是一种有潜力的新型抗肿瘤药物。本研究拟以超声微泡造影剂为载体，探索其介导新型小分子药物Nutlin3治疗眼内黑色素瘤的可行性及效率，为眼内肿瘤的治疗提供新的治疗方案。

眼内黑色素瘤是眼病中性质最严重、危害最大的一类。一直以来研究学者都在不断探索高效、安全、靶向的抗肿瘤方案。传统的放疗、化疗以及手术摘除均存在不同程.度视力损害及全身毒副作用，甚至致畸致残的危险。随着超声微泡技术的不断发展和可携带药物、基因的微泡造影剂的研制，超声微泡在肿瘤的诊断与治疗方面取得了进展。作为一种新型的药物载体，超声微泡具有无创、无毒、无放射污染等优点，能将携带的药物定向释放在靶组织，既减少药物在外周的破坏, 降低全身用药的副作用，又能显著提高局部组织的药物浓度。Nutlin3是近年来研发的咪唑其类小分子，能抑制MDM2与p53的相互作用，导致p53依赖的生长抑制，是一种有潜力的新型抗肿瘤药物。本研究以超声微泡造影剂为载体，探索了其介导新型小分子药物Nutlin3治疗眼内黑色素瘤的可行性及效率，为眼内肿瘤的治疗提供新的治疗方案。